How cost effective is Dexcom G6?
A long-term health economic analysis was performed to establish the cost-effectiveness for funding of the Dexcom G6 versus fingerstick testing. It examined UK-based type 1 diabetes patients with elevated HbA1c. The elevated levels can increase the risk of developing diabetes-related complications.
Dexcom G6 has been shown to have an incremental cost-effectiveness ratio (ICER) of £9,558 per QALY gained.
LBL022115 Rev002